Since no other posts have been added to this board, I wonder if anyone else is looking at LJPC? From a Foolish perspective, the company announced today the start of phase 3 trials on their lupus drug, LJP394. While this isn't quite a one horse company, it almost is. The value of the company then is tied to this drug and the success or failure of these trials. Given that most drugs don't make it to Phase 3 however, and of those that do, most go on to some level of comercialization, and given that the potential market is great for LJP394, it would seem to me that LJPC is a very Foolish play. Any other opinions out there?
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Rat